You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC

Key Lung Cancer Treatment Advances: The Down Low From Chicago

  • Authors: Charu Aggarwal, MD, MPH; Patrick Forde MBBCh; Ticiana Leal, MD; Joshua Sabari, MD
  • CME / ABIM MOC Released: 7/15/2022
  • Valid for credit through: 7/15/2023
Start Activity

  • Credits Available

    Physicians - maximum of 0.50 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 0.50 ABIM MOC points

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for oncologists, pathologists, pulmonologists, and other members of the lung cancer care team. 

The goal of this activity is that learners will be better able to understand the latest data evaluating treatment strategies for patients with lung cancer.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Data from key clinical trials evaluating lung cancer treatment strategies 
  • Have greater confidence in their ability to
    • Stay abreast of evolving treatment strategies used in patients with lung cancer 
    • Incorporate recent clinical trial data into the care of patients with lung cancer 


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Medscape policies. Others involved in the planning of this activity have no relevant financial relationships.


Faculty

  • Charu Aggarwal, MD, MPH

    Leslye M. Heisler Associate Professor
    Perelman School of Medicine
    University of Pennsylvania
    Philadelphia, Pennsylvania

    Disclosures

    Charu Aggarwal, MD, MPH, has the following relevant financial relationships: Relationships.
    Consultant or advisor for: AstraZeneca; BeiGene; Boehringer Ingelheim; Bluepring Genetics; Celgene; Daiichi Sankyo; Eisai; Genentech; Janssen; Lilly; Merck; Pfizer; Regeneron/Sanofi; Shionogi; Turning Point Therapeutics
    Research funding from: AstraZeneca/MedImmune; Genentech/Roche; Incyte; Macrogenics; Merck Sharp & Dohme

  • Patrick Forde, MBBCh

    Director, Thoracic Oncology Clinical Research Program
    Associate Professor of Oncology
    Johns Hopkins University
    Baltimore, Maryland

    Participation by Dr Forde does not constitute or imply endorsement by the Johns Hopkins University or the Johns Hopkins Hospital and Health System.

    Disclosures

    Patrick Forde, MBBCh, has the following relevant financial relationships:
    Consultant or advisor for: Amgen; AstraZeneca; BMS; Daiichi; Iteos; F Star; Genentech; GI; Janssen; Novartis; Sanofi; Surface
    Research funding from: AstraZeneca; BMS; Corvus; Kyowa; Novartis
    Other: DSMB for Polaris and Flame

  • Ticiana Leal, MD

    Associate Professor
    Director, Thoracic Medical Oncology Program
    Department of Hematology and Medical Oncology
    Winship Cancer Institute
    Emory University School of Medicine
    Atlanta, Georgia

    The opinions expressed are those of Dr Leal and do not necessarily reflect the views of Emory University or Emory Healthcare. Dr Leal’s participation in this activity does not constitute or imply endorsement by Emory University or Emory Healthcare.

    Disclosures

    Ticiana Leal, MD, has the following relevant financial relationships:
    Consultant or advisor for: Amgen; AstraZeneca; Bayer; Boehringer-Ingelheim; Blueprint; Daiichi-Sankyo; Eisai; EMD Serono; Genentech; Janssen; Jazz; Lilly; Merck; Mirati; Novocure; Roche; Takeda

  • Joshua Sabari, MD

    Assistant Professor of Medicine
    NYU Grossman School of Medicine
    Thoracic Medical Oncologist
    NYU Langone Health Perlmutter Cancer Center
    New York, New York

    Disclosures

    Joshua Sabari, MD, has the following relevant financial relationships:
    Consultant or advisor for: Astrazeneca; Genentech; Janssen; Mirati; Novartis; Pfizer; Sanofi Genzyme; Takeda

Editor

  • Amy Furedy, RN, OCN

    Medical Education Director, Medscape, LLC

    Disclosures

    Amy Furedy, RN, OCN, has no relevant financial relationships.

Compliance Reviewer

  • Amanda Jett, PharmD, BCACP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Amanda Jett, PharmD, BCACP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC

Key Lung Cancer Treatment Advances: The Down Low From Chicago

Authors: Charu Aggarwal, MD, MPH; Patrick Forde MBBCh; Ticiana Leal, MD; Joshua Sabari, MDFaculty and Disclosures

CME / ABIM MOC Released: 7/15/2022

Valid for credit through: 7/15/2023

processing....

Contents of This CME Activity

All sections of this activity are required for credit.

Updates on Targeted Therapy for NSCLC

Did you know that KRAS G12C mutations are present in about 14% of patients with NSCLC adenocarcinoma?
Joshua Sabari, MD

Updates on Immunotherapy for NSCLC

Did you know that immunotherapy has activity in the neoadjuvant setting in patients with early-stage NSCLC?
Charu Aggarwal, MD, MPH

Updates on the Management of Mesothelioma

Did you know that immunotherapy may improve outcomes in patients with mesothelioma?
Patrick Forde, MBBCh

Updates on the Management of Small Cell Lung Cancer

Did you know that, despite initial chemosensitivity, disease relapse is a significant problem for patients with SCLC, thus underscoring the need for new treatments?
Ticiana Leal, MD
 
  • Print